Kyowa Hakko USA, a wholly owned subsidiary of Kyowa Hakko Bio Co., Ltd., has completed Generally Regarded as Safe (GRAS) self-affirmation for its Setria Glutathione ingredient.

Setria L-Glutathione, a well-studied form of glutathione, is a tripeptide manufactured through a unique, patented process that can help replenish the body’s reserves that may be depleted through poor diet, pharmaceutical drugs and even the natural aging process. Setria provides intracellular antioxidant support, benefits cellular detoxification, supports a healthy immune response and supports a healthy aging process.

Found in virtually every cell of the body, glutathione plays essential roles in protein synthesis, synthesis and repair of DNA, enzyme function, transport, and cell maturation.

Optimal levels of glutathione have been associated with physical and mental health. Setria helps eliminate toxins, ingested chemicals and potential carcinogens that the body has already absorbed. It also intercepts and neutralizes toxins in the gastrointestinal tract before they are absorbed.
 
Setria Glutathione is successful sold as a key skin health ingredient around the world. A clinical study conducted at Thailand has evaluated the effect of glutathione on skin health. It is reported that the orally taken Setria in doses of 250mg per day may decrease melanin production, lightening skin in individuals with darker skin types.
 
Setria will be marketed by Kyowa Hakko USA as a food ingredient in the U.S. for use at levels of 5 mg/serving to 400 mg/serving in foods and beverages, including: